New Glioblastoma multiforme Research at Freifeld Lab funded by ERA-PerMed

Glioblastoma multiforme (GBM) is the most common malignant brain tumor and currently has no cure. As a member of the Glioma PerMed Consortium, a new project at Prof. Limor Freifeld’s Lab for Neuro-Engineering aims to develop personalized glioma invasion assays in preclinical models to better understand the heterogeneous behavior of Glioblastoma multiforme (GBM). The project will use unbiased machine learning algorithms developed in the Freifeld lab to determine GBM invasion behaviors, and the platform will also be used for drug screening. This is a critical first step towards personalized medicine for GBM patients.

This project is funded by the ERA-PerMed funding program for research in personalized medicine which supports interdisciplinary, innovative, and translational research proposals. In particular, this project combines the expertise of multiple research groups in glioma biology, organoid brain research, in vivo preclinical models, next-generation genomics, and personalized medicine.

Good luck to Limor and the research team!

Lab website>> https://neuroengineering.net.technion.ac.il/

Research opportunities:

>> https://bme.technion.ac.il/wp-content/uploads/2022/12/Lab_recruitment_slides_Nov_2022_N3_BMED_EE.pdf

More info about ERA-PerMed fund>> https://erapermed.isciii.es/joint-calls/joint-transnational-call-2022/